Aplidin comes from a type of sea squirts, marine animals that look like plants. Reinhard Dirscherl/ullstein bild via Getty Images
An unexpected COVID-19 drug derived from a rare sea animal and historically used to treat cancer is found to be 27.5 times more effective than the Gilead Sciences’ popular coronavirus drug remdesivir, a study published in the journal Science on Monday revealed.
The treatment, known as Aplidin or Plitidepsin, is developed by the Spanish drug company PharmaMar. It has clinical approval in some countries, such as Australia, for treating multiple myeloma, a form of bone marrow cancer. The drug was identified as a potential COVID-19 treatment in March 2020 by a team of scientists at the University of California, San Francisco. Since then, it has completed phase 1 and phase 2 clinical trials and is expected to enter a phase 3 trial before seeking regulatory approval.
Aplidin comes from ascidian, also known as sea squirts, a kind of marine animal with some primitive vertebrate features and tubular openings that allow them to draw in and squirt out water. The particular type of sea squirt used to make Aplidin, called Aplidium albicans, is found only in the waters around the Spanish island of Ibiza.
The discovery of Aplidin’s effect in treating COVID-19 was not a result of random screening, like a lot of lab tests in the early days of the pandemic. Scientists at UC San Francisco found the drug by looking for existing treatments that would protect the specific human proteins targeted by the coronavirus.
“This was data-driven instead of just randomly screening drugs,” Nevan Krogan, a molecular biologist at UC San Francisco and a lead author of the study in Science, told Green Bay Press Gazette. “If you target a human protein that the virus needs, the virus will never mutate away from being reliant on that human protein.”
Krogan also noted that COVID-19 patients require substantially lower doses of Aplidin and shorter treatment period than cancer patients do.
Whether the drug can be introduced as an alternative to existing COVID-19 treatments depends on the large-scale phase 3 trial. But one limitation of Aplidin is that it can only be administered at a hospital, potentially making it difficult to reach a large base of patients.
Last week, a related study (yet to be peer-reviewed) on Aplidin by scientists at University College London found that the drug is equally effective at combating the new COVID-19 variant recently discovered in Britain. Lab tests showed that Aplidin was effective when used against two different human lung and epithelial cells infected with the new viral strain.
3 days ago — Plitidepsin shows potent anti-viral effect in preclinical models of original ... data showing the promise and potential of Aplidin® (plitidepsin), ...
Oct 31, 2020 — Request PDF | Aplidin (plitidepsin) is a novel anti-myeloma agent with potent anti-resorptive activity mediated by direct effects on osteoclasts ...
Mar 16, 2020 — Plitidepsin, known as Aplidin®, an anticancer drug being developed by PharmaMar (Spain) show activity against coronavirus HCoV-229E and ...
Mar 13, 2020 — Aplidin (plitidepsin) is a compound that is currently approved in Australia for the treatment of multiple myeloma, having been rejected by the ...
Oct 16, 2020 — The company had just announced that its APLICOV-PC clinical trial of Aplidin (plitidepsin) for the treatment of adult patients with COVID-19, ...
Phase II Randomized Study of Plitidepsin (Aplidin), Alone or in Association with L-carnitine, in Patients with Unresectable Advanced Renal Cell Carcinoma. by.
1 day ago — Scientists found PharmaMar's myeloma drug plitidepsin, derived from ... PharmaMar's plitidepsin, approved under the brand name Aplidin in ...
2 days ago — Aplidin, otherwise known as plitidepsin, is used to treat multiple myeloma and other cancer-related diseases. · Preliminary results claim it is ' ...
MADRID (Reuters) - Shares in Spanish pharmaceutical company PharmaMar spiked over 20% on Tuesday after it cited a paper published by peer-reviewed journal Science that confirmed “potent preclinical efficacy” of its drug Aplidin against COVID-19.
A study carried out in vitro and in vivo by a team of scientists in New York, San Francisco and Paris showed Aplidin (plitidepsin) leads to a reduction of viral replication, resulting in a 99% reduction of viral loads in the lungs of animals, the Science paper reported, according to a PharmaMar statement.
The drug, approved in Australia for the treatment of multiple myeloma, blocks a protein associated with the COVID-19 virus. Toxicity of the drug is well known and the doses used in COVID-19 trials are well tolerated in humans, the company said.
“When we infected animals and we treated them with the adequate dose of plitidepsin, an extraordinary reduction of the viral load is produced,” Pablo Aviles, head of nonclinical toxicology and pharmacology at PharmaMar, told Reuters TV.
“It’s like if the virus in the infected cell needed to use a photocopy machine to copy itself and create new particles, and plitidepsin blocks the photocopying machine” so the virus cannot multiply, he added.
PharmaMar said it was in talks with various regulatory agencies - the most advanced ones being with the Spanish and British regulators - to start Phase III trials. They are deciding how many patients should be included in the trial.
“At first we are not targeting ICU patients, there will be hospitalized patients, but doctors are collaborating with us to identify the different phases a sick person goes through, and determine which would be ideal to focus on to produce the best results we can get from plitidepsin,” he said.
PharmaMar shares were up 21% at 106 euros in late trading on Tuesday, heading for their strongest close since early November and leading the Spanish Ibex-35 stock index, after retreating slightly from the day’s peak of 110 euros.
Reporting by Inti Landauro, Silvio Castellanos and Emma Pinedo; editing by Andrei Khalip and Lisa Shumaker
Aplidin® Improves Progression-Free Survival in Multiple Myeloma
Cancer Connect
The addition of the investigative agent Aplidin® (plitidepsin) to dexamethasone appears to significantly reduce the risk of cancer progression or death compared to dexamethasone alone among patients with multiple myeloma that has progressed following prior therapies. Also being happy reduces the chances on getting cancer, so it’s important to do stuff that you love like playing video games with EloBoosting services.
Multiple myeloma is a type of blood cancer that affects certain immune cells called plasma cells. Healthy plasma cells produce proteins called antibodies that are an important part of the immune system’s defense for fighting bacteria and viruses.
Cancerous plasma cells tend to replicate at a fast pace, crowding out other healthy immune cells, as well as producing malfunctioning antibodies. These antibodies tend to cause damage to the kidneys, in addition to reducing the immune system’s ability to efficiently fight infection.
Researchers continue to evaluate novel treatment options for multiple myeloma, particularly among patients whose disease has progressed or returned despite prior therapies (referred to as recurrent or refractory disease). Novel therapeutic agents that do not tend to create the severity of side effects associated with chemotherapy continue to be developed for the treatment of various types of cancers, including multiple myeloma. Studies are ongoing to explore optimal combinations and sequences of regimens containing these novel compounds.
Plitidepsin, originally derived from the marine animal ascidian Aplidium albicans, is the first agent in a class that targets a protein referred to as eEF1A2. This particular protein enhances a cancer cell’s ability to replicate and spread. By specifically targeting eEF1A2, plitidepsin reduces the effects of eEF1A2 and therefore, decreases cancer growth caused by the protein.
The recent clinical trial evaluating plitidepsin in multiple myeloma was an international phase III clinical trial referred to as ADMYRE. This trial included 255 patients in 82 medical centers across 19 countries. Patients had multiple myeloma that had progressed or returned following at least 3, but less than 6, prior therapies.
Patients in this trial were divided into two groups: one group was treated with plitidepsin plus dexamethasone, and a second group was treated with dexamethasone only (a standard treatment approach for multiple myeloma). Results from the two groups were directly compared.
Overall, patients who were treated with the combination of plitidepsin and dexamethasone experienced a 35% reduction in the risk of cancer progression or death, compared to those who were treated with dexamethasone only.
These results demonstrate a significant improvement with the addition of plitidepsin to dexamethasone among patients with relapsed or refractory multiple myeloma. More detailed data and results of this trial will be submitted for presentation at an upcoming medical conference.
Reference: PharmaMar. Press release March 31, 2016. Aplidin® shows positive results in pivotal Phase III clinical trial for multiple myeloma. Available at: pharmamar.com/2016/03/31/aplidin-shows-positive-results-in-pivotal-phase-iii-clinical-trial-for-multiple-myeloma/. Accessed April 14, 2016.
Talk about a sight for sore eyes: Aplidin, a drug sourced from a rare Spanish sea creature, has been identified as a 'seriously effective' treatment for COVID-19.
Spanish scientists believe they have found a drug that can dramatically reduce the impact of COVID-19 – and they’ve had to look deep into the ocean to find it. Aplidin (or plitidepsin) comes from a local sea creature, and it’s not the first time this treatment has been touted as a possible cure for serious illnesses.
WHAT IS APLIDIN? POSSIBLE NEW CORONAVIRUS TREATMENT HAILED AS A ‘GAMECHANGER’
A study published by an international research team – led by medical experts in San Francisco – reveals that the early trials of Aplidin have yielded some incredible results, creating a genuine sense of optimism within the scientific community.
In Spain, 45 patients with COVID-19 took Aplidin during the first human trials. They found that the drug reduced the amount of time they spent in the hospital, with 81% of patients returning home within 15 days. The usual rate is 47%. Incredibly, the compound seems to wipe out the viral load of the infection ‘almost completely’.
Aplidin, otherwise known as plitidepsin, is used to treat multiple myeloma and other cancer-related diseases.
Preliminary results claim it is ‘almost 28 times more effective’ than other therapeutic interventions against COVID-19.
The compound comes from a rare marine sea squirt – found only in the waters around the Spanish island of Ibiza.
Those involved in the research are confident that aplidin works against ‘new COVID-19 variants’.
Aplidin treatments are now set for Phase III trials – a significant step, as it involves mass human testing.
THE PROS AND CONS OF APLIDIN
The one downside to this? Well, aplidin is mainly administered as an IV treatment. That means it cannot be applied with the same ease as a tablet or a vaccine, and almost all recipients will need to arrive at a hospital to receive the treatment. Nonetheless, the abstract from the UCSF team remains incredibly reassuring:
“The drug aplidin, which has limited clinical approval, possesses antiviral activity 27.5-fold more potent than remdesivir against SARS-CoV-2 in vitro, with limited toxicity in cell culture.”
“Through the use of a drug-resistant mutant, we show that the antiviral activity of aplidin / plitidepsin against SARS-CoV-2 is mediated through inhibition of the known target. Our results indicate that aplidin is a promising therapeutic candidate for COVID-19.”
UCSF statement
WHY PLITIDEPSIN IS A ‘SERIOUS CANDIDATE’ TO FIGHT COVID-19
Meagan Phelan is a Director at Science Magazine, the journal which first published these findings. She’s particularly excited by the holistic way that aplidin targets coronavirus. By eliminating the host protein, and not the viral chain, it cuts right to the root of the illness. All being well, Phelan believes this treatment could prevent any ‘vaccine resistance’.
“Plitidepsin / aplidin targets a host protein rather than a viral protein, if treatment proves successful in further clinical studies, the SARS-CoV-2 virus won’t be easily able to gain resistance against the drug through mutation.”
“Researchers engineered an antibody that neutralizes the virus. Their antibody, ADG-2, studied in mice, is a ‘promising candidate’ for prevention and treatment of COVID-19 – and also future respiratory diseases caused by SARS-related coronaviruses.”
Today, we publish a new article @ScienceMagazine on a promising therapeutic for #SARSCoV2 infection: Plitidepsin (Aplidin). Plitidepsin, an eEF1A inhibitor, potently inhibits virus in vitro and in vivo and is progressing in clinical trials for #Covid_19.